BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

scientific article published on 29 January 2019

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3389/FONC.2019.00016
P932PMC publication ID6361844
P698PubMed publication ID30761268

P50authorMariana LazariniQ54376664
Fernanda Marconi RoversiQ87070778
Sara Teresinha Olalla SaadQ89663109
P2093author name stringAdriana da Silva Santos Duarte
Fernando Vieira Pericole
Fernanda Soares Niemann
Karla Priscila Vieira Ferro
Luciana Bueno de Paiva
P2860cites workThe bromodomain protein Brd4 insulates chromatin from DNA damage signallingQ24294320
Selective inhibition of BET bromodomainsQ24301009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyQ24563021
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodQ25938999
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromesQ46438891
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.Q49963122
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaQ27853375
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaQ29617201
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.Q33601156
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.Q33767762
Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage.Q34485631
Revised international prognostic scoring system for myelodysplastic syndromesQ34639717
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.Q34772133
Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular MatrixQ35684573
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsQ35859212
Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structureQ35879437
BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-CellQ35967957
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerQ36862936
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Q36926120
High level of BRD4 promotes non-small cell lung cancer progressionQ36962647
Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?Q37060144
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionQ37220129
Landscape of genetic lesions in 944 patients with myelodysplastic syndromesQ37571585
DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosisQ37977244
Epigenetics of myelodysplastic syndromesQ38163846
Stem cell origin of myelodysplastic syndromesQ38171230
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanomaQ38630705
The DNA damage-induced cell death response: a roadmap to kill cancer cellsQ38704734
Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemiasQ38709586
BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cellsQ38799987
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid LeukaemiaQ38837834
BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinomaQ38894148
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.Q39033630
BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.Q39036236
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemiaQ39063991
DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response.Q39531551
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.Q43102402
Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patientsQ44347691
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
acute myeloid leukemiaQ264118
azacitidineQ416451
P304page(s)16
P577publication date2019-01-29
P1433published inFrontiers in OncologyQ26839986
P1476titleBRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
P478volume9

Reverse relations

cites work (P2860)
Q98471230BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage
Q91825095BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST
Q92856196Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia
Q94948764Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Q90281630Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators
Q89884153Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML

Search more.